20
Participants
Start Date
December 31, 2003
Primary Completion Date
February 28, 2009
Study Completion Date
August 31, 2009
Capecitabine (Xeloda)
650 mg/m2 po bid Days 1-14 750 mg/m2 po bid Days 1-14 850 mg/m2 po bid Days 1-14 950 mg/m2 po bid Days 1-14
Gemcitabine
750 mg/m2 IV Days 1 \& 8 q 21 days
Swedish Medical Center Cancer Institute, Seattle
Roche Pharma AG
INDUSTRY
Swedish Medical Center
OTHER